Background/Aims: Multidrug resistance proteins (MDRs, including P-glycoproteins) are efflux pumps that serve important biological functions but hinder successful drug delivery to the CNS. Many chemotherapeutic agents, anti-epileptics, anti-HIV drugs, and opiates are substrates for MDRs. Therefore, understanding the regulation of MDRs in the endothelial cells composing the blood-brain barrier has therapeutic implications. Methods: We used microarray, real time RT-PCR, Western blotting, and uptake of vinblastine by RBE4 cerebral endothelial cells to test the effects of tumor necrosis factor alpha (TNF) on the expression and functions of Pglycoprotein (MDR1). Results: The proinflammatory cytokine TNF specifically induced the expression and enhanced the function of MDR1 in RBE4 cells. The persistent upregulation of MDR1 mRNA was shown by cDNA microarray at 6, 12, and 24 h after TNF treatment. This was confirmed by real-time RT-PCR between 2 and 24 h. MDR1 protein expression was increased 6 to 24 h after TNF treatment and resulted in a significant reduction in the cellular uptake of 3 H-vinblastine. Conclusion: The drug efflux transporter in cerebral endothelial cells can be upregulated by TNF. This suggests that adjunctive anti-TNF treatment has novel therapeutic potential in conditions such as brain cancer, epilepsy, neuroAIDS, and chronic pain.
Introduction
The multidrug resistance protein 1 (MDR1, or Pglycoprotein, a product of the MDR1 gene) is one of the most important efflux transporters belonging to the large family of ATP-binding cassette (ABC) transporters. The P-glycoprotein transporter expressed in the intestine, liver, and kidney is essential for drug absorption and disposition, and that at the blood-brain barrier (BBB) limits the permeation of a variety of drugs and toxins from blood to the CNS. Even the protease inhibitors used to treat human immunodeficiency virus type 1 (HIV-1) are substrates for P-glycoproteins . Structurally, the P-glycoproteins are integral membrane glycoproteins, consisting of two similar 854 halves of a six membrane spanning domain followed by a cytoplasmic domain where nucleotide binding takes place [2, 3] . There is a wide spectrum of substrates and many isoforms that show differential subcellular distribution.
The induction of MDR1 is largely responsible for the phenomenon of multiple drug resistance. MDR1 is expressed at the CNS barriers as well as in parenchymal tissue [4] [5] [6] [7] [8] [9] [10] . In brain tumors as well as many other disorders involving the CNS, drug delivery by peripheral routes is restricted by the presence of the blood-brain, blood-cerebrospinal fluid, and blood-tumor barriers. Once across these initial barriers, drug accumulation in the brain can be further restricted by active efflux transporters, like MDR1. Apart from the wide range of permeabilities related to the nature of the tumor, these efflux transporters actively reduce uptake of the drug [9] [10] [11] . Similar considerations apply to the treatment of epilepsy [12] and HIV-1 infection [13] . MDR1 in leukocytes reduces the cell uptake of protease inhibitors [14] , and permeation of protease inhibitors across the BBB in neuroAIDS would encounter the same challenge.
Morphine and endorphins are also substrates for Pglycoprotein [15] . By contrast, endomorphin transport across the BBB does not involve P-glycoprotein either in in-vivo [16] or in-vitro experiments [17] . Although endomorphin is more selective for the mu opiate receptor than endorphin, these two peptides have little structural similarity. Inhibition of P-glycoprotein activity by GF120918 prolongs morphine-induced antinociception in rats [18] , and another P-glycoprotein inhibitor, cyclosporine, as well as knockout of P-glycoprotein, increases the sensitivity of mice to a variety of opiates [19] .
Overall, it seems that many drugs and prodrugs are recognized either as substrates or inhibitors of MDR1. Several of these substances, including chemotherapy agents, anti-epileptics, anti-HIV-1 drugs such as protease inhibitors, and endogenous and exogenous opiates, in turn modulate MDR1 activity and serve as substrates [19] [20] [21] [22] . Thus, better understanding of how MDR1 is regulated will have a substantial impact on efficient drug delivery into the CNS.
Here we approach the problem of how neuroinflammation regulates the expression and function of MDR1. This is illustrated by use of tumor necrosis factor α (TNF), a proinflammatory cytokine that is produced with different time courses by all CNS parenchymal cells after trauma, hypoxia, and inflammation, resulting in elevated concentrations in the microcirculation [23] . TNF was originally identified as a macrophage-derived serum factor after endotoxin challenge causing hemorrhagic necrosis of mouse sarcoma Meth A and other transplanted tumors [24] . At the level of the BBB, TNF not only modulates the functions of the constituent endothelial cells and their tight junctions but also exhibits its own receptor-mediated transport [25] [26] [27] . We have shown that TNF specifically modulates the expression and functions of the receptors for leukemia inhibitory factor in the cerebral microvessel endothelial cell line RBE4 [28, 29] . How TNF regulates the functions of MDR1, a membrane protein encompassing 12-transmembrane domains [2, 3] , has not been fully characterized.
Nonetheless, regulation of MDR1 by proinflammatory cytokines has been observed in parenchymal cells of the liver and colon [30] [31] [32] [33] . Since TNF shows variable effects of either inducing or reducing MDR1 activity in these cells, its actions might depend on different cell types and treatment conditions. In BBB cells, one group of investigators initially found that TNF decreases MDR1 transport activity [34] , but recently reported that this activity increased at longer times while this manuscript was under initial review [35] . The potential biphasic changes again indicate the dynamics of regulation. As TNF production also shows dynamic changes associated with tumor progression, hypoxia, and inflammation, its induction or suppression of MDR1 activity may directly affect the efficacy of therapeutic interventions at different disease stages.
To better quantify the regulation of MDR1 by TNF and the underlying mechanisms, we used an established rat cerebral microvessel endothelial cell line RBE4 as a model system. RBE4 cells express MDR1 and another ABC transporter, MRP1 (multidrug resistance-associated protein), as do primary cultured brain endothelial cells [36] . RBE4 cells also express TNF receptors, and show a lack of acute toxicity when low doses of TNF are applied [37] . Thus, RBE4 cells constitute a suitable model to study MDR1 expression and function. We found a consistent increase of MDR1, but not MRP1, at different times after TNF treatment in a microarray analysis. The increase of MDR1 was confirmed by real-time RT-PCR and Western blot analysis. Functional correlation with the higher level of expression was shown by upregulated MDR1 transporter activity in endocytosis assays. Thus, therapy of CNS disorders should take into consideration the increased efflux pump activity induced by proinflammatory cytokines.
Materials and Methods
Cells and reagents RBE4 rat brain microvessel endothelial cells were kindly provided by Dr. Pierre-Oliver Couraud (Institute of Cochin, Paris, France). The cells were maintained in αMEM and F10 containing antibiotics and supplemented with 10% FBS and bFGF as previously reported [38] . Recombinant mouse TNF was obtained from Biosource (Camarillo, CA), and a final concentration of 5 -25 ng/ml was used to treat the cells. 3 H-vinblastine sulfate (10-15 Ci/mmol) was purchased from Amersham Biosciences (Piscataway, NJ).
Microarray
Groups of RBE4 cells were treated simultaneously with TNF and collected 0, 6, 12, or 24 h after TNF treatment, the 0 time being the untreated control. Total RNA was extracted from pelleted cells with an Absolutely RNA RT-PCR Miniprep kit (Stratagene, La Jolla, CA). Double-stranded cDNA was synthesized by reverse transcription, purified, and transcribed in-vitro into cRNA labeled with digoxigenin. The quantity and quality of purified cRNA were determined in an Agilent 2100 Bioanalyzer (Agilent Biotechnologies, Santa Clara, CA). The labeled sample cRNA was incubated with immobilized oligonucleotides from the whole rat genome in the hybridization plate, followed by sequential incubation with anti-digoxigenin antibody conjugated to alkaline phosphatase and chemiluminescent substrate. The luminescence was detected at an emission wavelength of 458 nm in a 1700 chemiluminescent microarray analyzer from Applied Biosystems (Branchburg, NJ). The original scans were analyzed by ABarray software (R package) and normalized for comparison between microarray chips. Probe IDs which showed more than 10-fold changes (p < 0.05) compared with control were uploaded to the Panther (Protein Analysis Through Evolutionary Relationships) Classification System to search for regulated proteins.
Real-time RT-PCR
Primer pairs and fluorescent probes for real-time RT-PCR were designed with Primer Express software (Applied Biosystems) and obtained from Integrated DNA Technologies (Coralville, IA). The primers for rat MDR1 were: forward 5'-AGC ACA CGT CTT TGG GAT CAC -3', reverse 5'-CCG AAC CGG AAA CAA GCA -3'. The fluorescent probe was 5'-FAM-TTC GCC TTC ACC CAG GCC ATG A-TAMRA-3'. Reactions for real-time PCR were performed on an ABI 7900 instrument with Taqman one-step RT-PCR master mix reagents (Applied Biosystems). The quantity of target mRNA in each sample was normalized to the control mRNA of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as described elsewhere [39] .
Western blotting
Cells were pelleted and lysed in RIPA buffer (100 mM NaCl, 10 mM Tris, pH 7.2, 0.1 % SDS, 1 % Triton X-100, 1 % deoxycholate, and 5 mM EDTA) in the presence of a protease inhibitor cocktail (Pierce, Rockford, IL). Protein concentrations were measured by bicinchoninic acid (BCA) assay (Pierce). Forty µg of whole cell lysates was separated on 7% SDSpolyacrylamide gels, and proteins were transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). After blocking with 5% non-fat dry milk, the membranes were probed with rabbit polyclonal antibodies specific to MDR (Santa Cruz Biotechnology, Santa Cruz, CA) and horseradish peroxideconjugated secondary antibodies (Amersham Biosciences) in phosphate-buffered saline (PBS) containing 0.1% Tween 20 and 0.5% milk. β-actin was also probed as a loading control. The signals were developed with enhanced chemiluminescence (ECL)-plus Western blotting detection reagents (Amersham Biosciences). All findings were confirmed in replicate studies.
Drug accumulation assay to determine MDR1 function RBE4 cells were seeded onto a 12-well plate and allowed to grow to 90% confluence. Two groups of cells were studied simultaneously (n = 3 wells/group) for each time point: PBS treatment or TNF treatment (5 ng/ml) for 6 h. The cells were preequilibrated in 0.25 ml transport buffer (α-MEM and F-10 containing 0.5 % bovine serum albumin and 20 mM HEPES) at 37°C for 30 min immediately before the assay. Cellular uptake of H-vinblastine was collected, and the cells were quickly washed with ice-cold PBS three times. The cells were collected in 0.25 ml of PBS containing 1% SDS, and further solubilized by addition of 0.5 ml of Solvable (Packard Biosciences, Meriden, CT) with overnight incubation at 50°C in a shaking water bath. After addition of UltimaGold scintillation cocktail (PerkinElmer, Waltham, MA) and incubation at room temperature overnight, the β-radioactivity in the samples was measured in an LS5000 scintillation counter (Beckman Coulter, Fullerton, CA). The percentage of internalized radioactivity was calculated. Group differences were determined by one-way analysis of variance. 
Results

TNF upregulates MDR1, 2, 3 as shown by microarray
Panther analysis showed that there were 72 genes having more than a 10-fold upregulation (p < 0.05) after 6 h of TNF treatment, 48 genes at 12 h, and 35 genes at 24 h. The gene products included those involved in cellular membrane function, transport, cytokine signaling, cell adhesion, growth, differentiation, and extracellular matrix functions. Among these proteins, only a few showed persistent changes at all time points tested. MDR1, 2, 3 showed consistent upregulation, most pertinent to our studies on blood-brain and blood-tumor barriers. The more than 10-fold increase of the mRNA of MDRs suggests the specificity of the findings.
Real-time RT-PCR verifies increased MDR1 mRNA
To verify the findings of increased MDR1 mRNA shown by microarray, RBE4 cells were treated with an even lower dose of TNF (5 ng/ml) for 0, 0.5, 1, 2, 6, and 24 h, the 0 time being the PBS vehicle-treated control. Real-time RT-PCR showed that TNF induced a timedependent increase of MDR1, which was significant by 2 h and was most pronounced at 24 h (Fig.1) . The results were normalized to the mRNA of the housekeeping gene GAPDH.
MDR1 protein is upregulated by TNF treatment
Time-dependent induction of MDR1 protein in RBE4 cell lysate was shown by semi-quantitative Western blot analysis with β-actin as an internal control. The increase was pronounced at 6 h, and continued to increase at 12 and 24 h (Fig.2) . This is consistent with the induction of MDR1 mRNA which exhibited an earlier onset.
Increased MDR1 function results in reduced cellular uptake of vinblastine
In RBE4 cells, the baseline uptake of 3 H-vinblastine was high. The accumulation of radioactivity inside the cells was most rapid in the first 30 min, and gradually 
reached a plateau. In cells 6 h after TNF treatment, 3 H-vinblastine uptake was significantly lower than in the control group at all time points tested (p < 0.005) (Fig.3) . Since the extracellular concentration (amount of vinblastine available for uptake) was significantly higher than that inside the cells, the nonlinear relationship between the %endocytosis and time of incubation indicates the presence of an efflux pump for vinblastine. This efflux system showed a greater capacity in the presence of TNF, reflected by the lower percent accumulation of vinblastine at all time points tested and a similar plateau.
Discussion
Our results show that TNF treatment induced a pronounced increase of MDR1 mRNA and protein expression. This led to upregulation of transporter activity, with less vinblastine taken up by the cells. Vinblastine is a known substrate for MDR1, and its reduced uptake by the cells reflects activation of MDR1 [40] . The findings suggest that increased production of TNF, such as by CNS tumor or inflammation, can activate efflux transport at the BBB and alter the efficacy of CNS therapeutics.
RBE4 cerebral microvessel endothelial cells express receptors for TNF and show dose-and time-related changes in γGT activity and ATP production in response to TNF. Overall, TNF treatment results in a reduction of cellular metabolism shown by decreased levels of ATP [37] . MDR1 activity is dependent on binding and utilization of ATP [41] . Thus, in the presence of reduced cellular ATP production, the upregulation of MDR1 by TNF assumes added significance. Since brain tumors are often associated with necrosis and inflammation of the surrounding brain parenchyma, TNF produced in-situ may serve as an autocrine or paracrine factor to activate MDRs.
We showed by microarray that MDR1,2,3 were upregulated in RBE4 cells by TNF treatment, and focused on MDR1 in the current study. Regina et al. reported that another ABC transporter, MRP1 (multidrug resistance-associated protein), as well as MDR1, are present in primary cultured brain endothelial cells [36] . However, our microarray analysis did not detect more than a 10-fold of increase of MRP1 or other ABC transporters. This makes the finding of MDR1 upregulation more specific.
The TNF-mediated upregulation of MDR1 expression and function in endothelial cells may be involved in the variability of tumor responses to chemotherapy. MDR1 is mainly located at the apical surface of endothelial cells [42] . TNF can be produced by cancer cells, microglia and other cell types in the CNS parenchyma, and it enters the cerebral microcirculation through a relatively leaky barrier as a result of tissue necrosis, inflammation, and hypoxia. Thus, TNF can activate MDR1 at the luminal side of the endothelial cells, where most BBB efflux transporters are located, to reduce drug penetration. Similarly, TNF concentration in the microcirculation may be elevated in systemic inflammation leading to brain abscess, neuroAIDS, epilepsy, and chronic pain syndromes. Since the permeability of the BBB to TNF shows a circadian rhythm, particularly in the spinal cord region [43] , the activity of MDR1 also may be subject to circadian regulation.
The RBE4 in-vitro BBB system also serves as a good model for dissection of the downstream events after TNF binding to its receptors that eventually lead to transcriptional regulation of MDR1, as we showed by microarray and real-time PCR. One of the major effector molecules for TNF signaling is nuclear factor (NF)-κB. An NF-κB binding site has been identified within the rat MDR1b promoter [44] . This has facilitated our ongoing investigation of MDR1 promoter regulation by TNF in RBE4 cells.
The finding that MDR1 in endothelia was subject to regulation by TNF also points to the possibility that other proinflammatory cytokines may play regulatory roles in the uptake of vinblastine and other substrates for MDR1. This opens the new prospect of anti-TNF or antiinflammatory treatment to enhance the efficacy of delivery of CNS drugs that are affected by the MDR1 efflux transporter, such as some chemotherapeutic agents, anti-epileptics, anti-AIDS, analgesics, and antiAlzheimer's disease medications.
